Director, Market Access Value and Access at Acadia Pharmaceuticals

Conshohocken, Pennsylvania, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biopharmaceutical, PharmaceuticalsIndustries

Requirements

Expertise in translating complex clinical, economic, and real-world evidence into compelling value propositions for U.S. payers (Commercial, Medicare, Medicaid)
Ability to develop and adapt value communication resources tailored to Key Account Directors (KADs), Regional Account Directors (RADs), National Access Directors (NADs), including payer value decks, cost-impact claims, and summary tools
Experience aligning content with local market dynamics, formulary criteria, and institutional drivers for IDNs, GI super groups, and regional managed care organizations
Strong cross-functional collaboration skills with Market Access, Brand Marketing, HEOR, Medical, and Field Access teams
Capability to integrate brand strategy into payer messaging across patient, HCP, and payer channels
Proficiency in overseeing cost-effectiveness analyses, budget impact models, and population health value tools
Knowledge of payer scrutiny, policy shifts, competitive pressures, and evolving payer needs in the biopharmaceutical context, particularly for MASH/NASH therapies

Responsibilities

Develop and execute comprehensive value communication strategies to drive payer coverage, reimbursement, and pull-through across Commercial, Medicare, and Medicaid markets
Lead the development of payer value stories and messaging resources supported by clinical evidence and health economics data
Tailor value narratives to specific payer archetypes and coverage scenarios, anticipating access barriers and justifying formulary inclusion
Continuously refine the value proposition based on payer needs, policy shifts, and competitor developments
Collaborate with HEOR and Medical to align payer messaging with evidence generation and scientific narratives
Translate clinical trial data, real-world evidence, and economic analyses into actionable payer insights
Oversee development of cost-effectiveness analyses, budget impact models, and population health value tools with HEOR
Work with commercial teams to embed access and affordability messaging into HCP engagement plans and marketing tactics
Create payer engagement materials (objection handlers, FAQs, scenario-based tools) for NADs, RADs, and KADs
Develop and lead training initiatives for NADs, RADs, and KADs on communicating clinical and economic value

Skills

Market Access

Payer Strategy

HEOR

Value Communication

Real-World Evidence

Economic Analysis

Formulary Management

Managed Care

Medicare

Medicaid

Account Management

Brand Positioning

Cross-Functional Collaboration

Strategic Planning

Payer Decks

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About Acadia Pharmaceuticals

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Dallas, TexasHeadquarters

1993Year Founded

$813.4MTotal Funding

ACQUISITIONCompany Stage

Biotechnology, HealthcareIndustries

501-1,000Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Risks

Increased competition in CNS drug market may impact Acadia's market share.

Potential clinical trial delays could affect drug approval timelines.

Dependence on partnerships poses risks if collaborations face challenges or dissolve.

Differentiation

Acadia focuses on CNS disorders with unmet medical needs, like Parkinson's and Rett syndrome.

The company has a strong R&D foundation, developing innovative small molecule drugs.

Acadia's strategic partnerships enhance its research capabilities and market reach.

Upsides

Acadia's collaboration with Saniona expands its portfolio with SAN711 for neurological disorders.

Health Canada's approval of Daybue boosts Acadia's presence in the Canadian market.

The rise of personalized medicine aligns with Acadia's targeted therapy approach.

Land your dream remote job 3x faster with AI

Try Jobo Free